By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aquinox Pharmaceuticals 

5600 Parkwood Way
Suite 430
Richmond  British Columbia  V6V 2M2  U.S.A.
Phone: 604-629-9223 Fax: 604-295-4748




Company News
Aquinox (AQXP)'s AQX-1125 Flunks Mid Stage Study for Patients With Atopic Dermatitis 11/3/2015 6:19:01 AM
Aquinox (AQXP) Presents At 2015 International Society For The Study Of BPS Conference 9/21/2015 10:27:48 AM
Aquinox (AQXP) To Host R&D Day In New York 9/21/2015 10:26:30 AM
Aquinox (AQXP) Announces Closing Of $98.0 Million Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/16/2015 8:34:50 AM
Aquinox (AQXP) Prices Public Offering Of Common Stock 9/10/2015 7:29:04 AM
Aquinox (AQXP) Announces Proposed Public Offering Of Common Stock 9/9/2015 7:47:46 AM
Aquinox (AQXP) Announces Positive Results From Secondary Endpoints From Phase II LEADERSHIP Trial In BPS/IC And Reports Second Quarter 2015 Financial Results 8/6/2015 3:06:01 PM
Aquinox (AQXP) To Present At The Canaccord Genuity 35th Annual Growth Conference 8/5/2015 11:08:08 AM
Aquinox (AQXP) Announces Results From FLAGSHIP Trial With AQX-1125 In Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations 7/9/2015 7:20:32 AM
Aquinox (AQXP)’s Bladder Pain Drug Fails to Meet Statistical Endpoint in Phase II Trial 6/25/2015 7:29:05 AM